Corium International,Inc. (NASDAQ:CORI) Files An 8-K Results of Operations and Financial Condition
Item2.02.Results of Operations and Financial Condition.
OnNovember 21, 2016, Corium International,Inc. (the Company)
issued a press release to announceits financial results for its
fourth fiscal quarterand fiscal year ended September 30, 2016.A
copy of the press release is furnished as Exhibit 99.1 to this
report and is incorporated herein by reference.
The information furnished under Item 2.02 of this report,
including Exhibit 99.1, shall not be deemed filed for purposes of
Section 18 of the Securities Exchange Act of 1934, as amended
(the Exchange Act), or otherwise subject to the liabilities of
that section, nor shall it be deemed incorporated by reference
into any other filing under the Securities Act of 1933, as
amended, or the Exchange Act, except as expressly set forth by
specific reference in such a filing.
Item9.01. Financial Statements and Exhibits.
(d)Exhibits.
|
Exhibit Number |
Description |
|
99.1 |
Press release dated November 21, 2016. |
2
About Corium International, Inc. (NASDAQ:CORI)
Corium International, Inc. is a biopharmaceutical company. The Company is engaged in the development, manufacture and commercialization of specialty pharmaceutical products that focuses on transdermal and transmucosal delivery systems. Its development platforms enable transdermal delivery of large molecules, or biologics, including vaccines, peptides and proteins, as well as small molecules. Its Corplex and MicroCor platforms address the shortcomings of traditional transdermal drug delivery. Its marketed products include Clonidine TDS, which is a treatment for hypertension; Fentanyl TDS, which is a treatment for management of chronic pain, and Crest Whitestrips are a series of five products for oral care. Its Twirla is designed to deliver both hormones at levels comparable to low-dose oral contraceptives. Its MicroCor hPTH(1‑34) is a transdermal system designed to use its MicroCor technology to provide the delivery of parathyroid hormone. Corium International, Inc. (NASDAQ:CORI) Recent Trading Information
Corium International, Inc. (NASDAQ:CORI) closed its last trading session down -0.26 at 4.82 with 8,699 shares trading hands.
